Evidence map›Paper›PMID 42764349›Full record

ArticleNature communications2026

Six-compound cocktail for maturation of human pluripotent stem cell-derived liver spheroids for toxicity prediction.

Lipeng Tian, Faiza H Anas, Ryan Hasselkus, Elsa Joseph, Michelle Chadraa, Baran Koç, Wei Wu, Bhavana Karnam, Pablo Flores-Muñoz, Ariel Alon and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lipeng TianQuris Technologies INC., 38 Wareham St., Boston, MA, USA. lipeng@quris.ai.ORCID http://orcid.org/0000-0002-8870-1578
Faiza H AnasQuris Technologies INC., 38 Wareham St., Boston, MA, USA.
Ryan HasselkusQuris Technologies INC., 38 Wareham St., Boston, MA, USA.ORCID http://orcid.org/0000-0002-0710-8722
Elsa JosephQuris Technologies INC., 38 Wareham St., Boston, MA, USA.
Michelle ChadraaQuris Technologies INC., 38 Wareham St., Boston, MA, USA.
Baran KoçQuris Technologies INC., 38 Wareham St., Boston, MA, USA.ORCID http://orcid.org/0000-0001-6519-3104
Wei WuQuris Technologies INC., 38 Wareham St., Boston, MA, USA.
Bhavana KarnamQuris Technologies INC., 38 Wareham St., Boston, MA, USA.
Pablo Flores-MuñozQuris Technologies INC., 38 Wareham St., Boston, MA, USA.
Ariel AlonQuris Technologies LTD., 6 HaNatsiv Street, Tel Aviv, Israel.
Jessica MorrisQuris Technologies INC., 38 Wareham St., Boston, MA, USA.
Isaac BentwichQuris Technologies LTD., 6 HaNatsiv Street, Tel Aviv, Israel.
Amir BeinQuris Technologies INC., 38 Wareham St., Boston, MA, USA. amir@quris.ai.ORCID http://orcid.org/0000-0002-5552-6179

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury remains a leading cause of drug development failure and a major clinical safety concern. Human induced pluripotent stem cell-derived hepatocytes offer a promising approach for modeling patient-specific drug responses, but their immature phenotype limits predictive performance. We report a chemically defined six-compound maturation strategy for human stem cell-derived liver spheroids. Matured spheroids acquire adult-like hepatic features, including increased cytochrome P450 activity, enhanced metabolic capacity, and a metabolic shift toward oxidative phosphorylation, supported by genome-wide pathway analysis and functional assays across multiple donors. When evaluated with twenty reference compounds, matured spheroids improve hepatotoxicity prediction and outperform primary human hepatocyte spheroids. Free fatty acids treatment further  induces features of metabolic dysfunction-associated steatotic liver disease and increases sensitivity to selected hepatotoxic drugs. In this work, we show that a defined six-compound cocktail enhances stem cell-derived liver spheroids maturation, improves drug-induced hepatotoxicity prediction, and enables modeling of steatotic liver disease.

Indexed as

Chemical and Drug Induced Liver InjuryHepatocytesInduced Pluripotent Stem CellsLiverPluripotent Stem CellsSpheroids, CellularCell DifferentiationCytochrome P-450 Enzyme SystemHumansCytochrome P-450 Enzyme System

Identifiers

PMID42764349
PMCPMC13590590

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.